EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Levodopa Carbidopa Intestinal Gel in Advanced Parkinson’s Disease: DUOGLOBE Final 3-Year Results

K Ray Chaudhuri, Norbert Kovács, Francesco E Pontieri, Jason Aldred, Paul Bourgeois, Thomas L Davis, Esther Cubo, Marieta Anca-Herschkovitsch, Robert Iansek, Mustafa S Siddiqui, Mihaela Simu, Lars Bergmann und 5 weitere

Journal of Parkinson’s Disease · 16.06.2023 · 13 (5) · 769-783

DOI: 10.3233/jpd-225105 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Journal of Parkinson’s Disease, online erschienen am 05.06.2023. Verfasst von K Ray Chaudhuri und 16 weiteren Autor:innen. Beteiligte Einrichtung: Parkinson's Foundation International Centre of Excellence, King's College Hospital, and King's College Institute of Psychiatry, Biomedical Research C…. Hauptthemen laut MEDLINE: Levodopa, Parkinson Disease. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Levodopa-carbidopa intestinal gel (LCIG) improves motor and non-motor symptoms in patients with advanced Parkinson’s disease (aPD).

Objective

To present the final 36-month efficacy and safety results from DUOGLOBE (DUOdopa/Duopa in Patients with Advanced Parkinson’s Disease – a GLobal OBservational Study Evaluating Long-Term Effectiveness; NCT02611713).

Methods

DUOGLOBE was an international, prospective, long-term, real-world, observational study of patients with aPD initiating LCIG in routine clinical care. The primary endpoint was change in patient-reported “Off” time to Month 36. Safety was assessed by monitoring serious adverse events (SAEs).

Results

Significant improvements in “Off” time were maintained over 3 years (mean [SD]: –3.3 hours [3.7]; p < 0.001). There were significant improvements to Month 36 in total scores of the Unified Dyskinesia Rating Scale (–5.9 [23.7]; p = 0.044), Non-Motor Symptoms Scale (–14.3 [40.5]; p = 0.002), Parkinson’s Disease Sleep Scale-2 (–5.8 [12.9]; p < 0.001), and Epworth Sleepiness Scale (–1.8 [6.0]; p = 0.008). Health-related quality of life and caregiver burden significantly improved through Months 24 and 30, respectively (Month 24, 8-item Parkinson’s Disease Questionnaire Summary Index, –6.0 [22.5]; p = 0.006; Month 30, Modified Caregiver Strain Index, –2.3 [7.6]; p = 0.026). Safety was consistent with the well-established LCIG profile (SAEs: 54.9% of patients; discontinuations: 54.4%; discontinuations due to an adverse event: 27.2%). Of 106 study discontinuations, 32 patients (30.2%) continued LCIG outside the study.

Conclusion

DUOGLOBE demonstrates real-world, long-term, reductions in motor and non-motor symptoms in patients with aPD treated with LCIG.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LevodopaParkinson DiseaseHumansCarbidopaAntiparkinson AgentsProspective StudiesQuality of LifeDrug CombinationsGels

Stichwörter der Autor:innen

DUOGLOBEParkinson’s diseasedyskinesialevodopa-carbidopa intestinal gelreal-world data

Substanzen

carbidopa, levodopa drug combinationLevodopaCarbidopaAntiparkinson AgentsDrug CombinationsGels

Autor:innen und Institutionen

  • Parkinson's Foundation International Centre of Excellence, King's College Hospital, and King's College Institute of Psychiatry, Biomedical Research Centre, Psychology & Neuroscience, London, United Kingdom.
  • Department of Neurology, University of Pécs, Pécs, Hungary.
  • Department of Neuroscience, Mental Health and Sensory Organs, Sapienza University of Rome, Rome, Italy.
  • Santa Lucia Foundation, IRCCS, Rome, Italy.
  • Selkirk Neurology, Spokane, WA, USA.
  • Department of Neurology AZ Groeninge, Kortrijk, Belgium.

Zitieren

APA

Chaudhuri, K. R., Kovács, N., Pontieri, F. E., Aldred, J., Bourgeois, P., Davis, T. L., Cubo, E., Anca-Herschkovitsch, M., Iansek, R., Siddiqui, M. S., Simu, M., Bergmann, L., Ballina, M., Kukreja, P., Ladhani, O., Jia, J., & Standaert, D. G. (2023). Levodopa Carbidopa Intestinal Gel in Advanced Parkinson’s Disease: DUOGLOBE Final 3-Year Results. Journal of Parkinson’s Disease, 13(5), 769-783. https://doi.org/10.3233/jpd-225105

Vancouver

Chaudhuri KR, Kovács N, Pontieri FE, Aldred J, Bourgeois P, Davis TL, et al. Levodopa Carbidopa Intestinal Gel in Advanced Parkinson’s Disease: DUOGLOBE Final 3-Year Results. Journal of Parkinson’s Disease. 2023;13(5):769-783. doi:10.3233/jpd-225105

BibTeX
@article{Chaudhuri2023,
  author = {Chaudhuri, K Ray and Kovács, Norbert and Pontieri, Francesco E and Aldred, Jason and Bourgeois, Paul and Davis, Thomas L and Cubo, Esther and Anca-Herschkovitsch, Marieta and Iansek, Robert and Siddiqui, Mustafa S and Simu, Mihaela and Bergmann, Lars and Ballina, Mayra and Kukreja, Pavnit and Ladhani, Omar and Jia, Jia and Standaert, David G},
  title = {Levodopa Carbidopa Intestinal Gel in Advanced Parkinson’s Disease: DUOGLOBE Final 3-Year Results},
  journal = {Journal of Parkinson’s Disease},
  year = {2023},
  volume = {13},
  number = {5},
  pages = {769--783},
  doi = {10.3233/jpd-225105}
}
Kostenlos starten →